Bone marrow-derived cells have important roles in cancer development and progression. Our previous studies demonstrated that murine bone marrow-derived myofibroblasts (BMFs) enhanced tumor growth. In this study, we investigated the mechanisms of BMF actions. We found that co-injection of BMFs with gastric cancer cells markedly promoted tumorigenesis. Co-cultured BMFs or BMF-conditioned medium (BMF-CM) induced the formation of spheres, which expressed stem cell signatures and exhibited features of self-renewal, epithelial-to-mesenchymal transition and tumor initiation. Furthermore, CD44 + fractions in spheres were able to initiate tumorigenesis and re-establish tumors in serially passaged xenografts. In co-culture systems, BMFs secreted high levels of murine interleukin-6 (IL-6) and hepatocyte growth factor (HGF), whereas cancer cells produced high level of transformation growth factor-β1 (TGF-β1). BMF-CM and IL-6 activated BMFs to produce mHGF, which activated signal transducer and activator of transcription 3 (STAT3) and upregulated TGF-β1 in human cancer cells. In return, cancer cell-CM stimulated BMFs to produce IL-6, which was inhibited by anti-TGF-β1 neutralizing antibody. Blockade of HGF/Met, Janus kinase 2 (JAK2)/STAT3 and TGF-β1 signaling by specific inhibitors inhibited BMF-induced sphere formation. STAT3 knockdown in cancer cells also inhibited BMF-induced sphere formation and tumorigenesis. Moreover, TGF-β1 overexpression in cancer cells was co-related with IL-6 and HGF overexpression in stromal cells in human gastric cancer tissues. Our results show that BMF-derived IL-6/HGF and cancer cell-derived TGF-β1 mediate the interactions between BMFs and gastric cancer cells, which regulate cancer stemness and promote tumorigenesis. Targeting inhibition of the interactions between BMFs and cancer cells may be a new strategy for cancer therapy.
INTRODUCTION
Accumulating evidence has shown that tumor stroma has important roles in cancer initiation and progression. 1 Tumor stromal cells include bone marrow (BM)-derived myeloid cells and lymphoid cells, mesenchymal stem cells (MSCs), myofibroblasts and endothelial progenitor cells. However, the contributions of these different stromal cells to tumorigenesis remain unknown. The BM-derived myofibroblasts (BMFs), a major cell type of stromal cells, 2 have been shown to constitute a MSC niche. 3 BMF infiltration to the gastric tissues is associated with gastric cancer development. 4 BMFs have also been demonstrated to enhance tumor development and invasion. 3, 5 However, the underlying mechanisms by which BMFs promote tumorigenesis remain largely unknown.
Cancer stem cells (CSCs) or CSC-like cells (CSC-LCs) have been shown to have important roles in tumorigenesis and tumor progression in many types of tumors, 6, 7 including gastric cancer. 8 CSCs are a sub-population of tumor cells and are featured by their capabilities of self-renewal and tumor initiation. 6 CSCs can be regulated by their stromal microenvironment. 9, 10 Studies have shown that tumor stromal cells, including myofibroblasts, 10 MSC, 11 endothelial cells 12 and tumor-associated macrophages, 13 induce CSC-like sphere formation of cancer cells. However, whether BMFs promote tumorigenesis by induction of CSC-LCs remains unclear.
The interactions between stromal cells and cancer cells have pivotal roles in tumorigenesis and metastasis. 9, 14 Tumor myofibroblast-derived factors induced epithelial cell transformation in co-culture systems and tumorigenesis in xenograft models. 15 Conditional inactivation of the bone morphogenetic protein type II receptor in the stroma increased the myofibroblast population, causing colon epithelial hyperplasia. 16 Further studies have shown that MSC-derived interleukin-6 (IL-6) activates Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling in colon cancer cells and induces sphere formation of cancer cells. 11 Colon myofibroblast-secreted hepatocyte growth factor (HGF) was shown to reprogram differentiated colon cancer cells to CSC-LCs through AKT/Wnt signaling. 10 Our previous studies showed that BMFs secreted higher levels of cytokines (for example, IL-6), chemokines (for example, SDF1), growth factors (for example, IGF2), and matrix metalloproteinases (MMPs) (for example, MMP13), and exhibited stronger capabilities of tumorigenesis and tumor invasion than resident fibroblasts. 3 Nevertheless, out of these factors derived from BMFs, the factors that mediate the activation of cancer cells remain to be investigated. In return, how cancer cells regulate BMFs is also largely unknown.
In this study, we investigated the interactions between BMFs and gastric cancer cells. Our results showed that BMF-derived IL-6 and HGF and cancer cell-derived transformation growth factor-β1 (TGF-β1) mediated the interactions between BMFs and cancer cells, and these interactions contribute to the induction of CSC-LCs and promote tumorigenesis.
RESULTS

BMFs promote tumorigenesis of gastric cancer cells
Our previous study have shown that BMFs have stronger capacity to enhance tumor growth than wild-type fibroblasts. 3 We then further focused on the study of the effects of BMFs on tumorigenesis in mice injected with small number of cancer cells. We found that BMFs enhanced tumorigenesis and tumor growth when BMFs were co-injected with 10 4 gastric cancer cell MFC into mice (Figure 1a (Figure 1d ). Our previous study showed that CD44 + gastric cancer cells were stem cells (CSCs), whereas CD44 − MKN45 cells were non-CSCs and could not form spheres. 8 We found that BMFs also enhanced tumorigenesis in CD44 − MKN45 cells (Figure 1e ). However, mice injected with BMFs (2 × 10 6 cells) alone did not form tumors (data not shown). The results show that the co-injected BMFs in vivo promote tumorigenesis.
BMFs induce sphere formation of gastric cancer cells To investigate whether BMF-promoted tumorigenesis is due to inducing CSCs, we determined the effects of BMFs on stem-like sphere formation. When co-cultured with BMFs, MKN45 cells (95% of which were CD44 + cells) formed more and larger spheres than MNK45 cells cultured alone (Figure 1f ). The co-cultured BMFs also induced sphere formation of mouse gastric cancer MFC cells (Figure 1g ), human colon cancer cells SW620 and liver cancer HepG2 cells (Supplementary Figure 1B) . We further explored whether BMFs induce non-CSCs to form spheres. We sorted CD44 + and CD44 − MKN45 cells and co-cultured them with BMFs. Both CD44 + and CD44 − MKN45 cells formed more spheres when co-cultured with BMFs, compared with those cultured alone (Supplementary Figure 1C) Figures 1D and 1E ). To further investigate the effects of BMFs on non-CSCs, by using CD44 deficient (CD44 − ) MKN28 gastric cancer cells. 8 We observed that MKN28 cells (EGFP − cells) formed spheres when co-cultured with BMFs (EGFP + cells), whereas MKN28 cells cultured alone in stem cell medium (SCM) did not (Figure 1h) . The results indicate that BMFs induce sphere formation of CD44 − non-CSCs. To determine whether BMF-induced sphere formation is independent on cell-cell contact, we used a transwell co-culture system in which MKN28 cells and BMFs were seeded separately into lower and upper transwells (Supplementary Figure 2A) . The 0.4 μm filter between the two wells blocks cell penetration but allows media communication. The indirectly co-cultured MKN28 cells with BMFs formed more and larger spheres than MKN28 cells indirectly co-cultured with the control HEK293 cells (Supplementary Figure 2A) . Furthermore, BMF-CM and co-culture-CM significantly increased the sphere formation of MFC, MKN28 and MKN45 cells compared with the SCM, and co-culture-CM exhibited the strongest induction of sphere formation ( Figure 1g and Supplementary Figures 2B and 2C) . The results suggest that BMF-derived factors contribute to the sphere formation of cancer cells.
BMF-induced spheres exhibit CSC properties
To determine whether BMF-induced spheres have CSC properties, we digested spheres into single cells and seeded the single cells into ultralow attachment plates. We observed that BMF-CMinduced MKN28 spheroid cells (first-generation spheres) formed second-generation spheres in SCM (Figures 2a and b) , confirming that BMF-induced MKN28 spheres (referred to as MKN28-CSC-LCs) possess the self-renewal feature, one of the CSC properties. When cultured in attachment culture plates, the MKN28-CSC-LCs exhibited mesenchymal-like morphology, whereas the parental MKN28 cells did not (Figure 2a ). When cultured in SCM, MKN-28-CSC-LCs form more spheres than MKN-28 cells alone (Figure 2b ). Western blot showed that the expression of vimentin, snail and TGF-β1 was higher, whereas the expression of E-cadherin was lower in MKN28-CSC-LCs than those in parental cells (Figure 2c ). These results indicate that MKN28-CSC-LCs possess epithelial-to-mesenchymal transition (EMT) characteristics, one of CSC features. 17 Microarray analysis showed that BMF-induced MKN28-CSC-LCs overexpressed multiple signaling molecules of CSCs (Supplementary Figure 3A) , including CD10 (breast tissues stem cell and breast CSC marker), 18 KIAA1199 (Wnt/β-catenin pathway), 19 Hey-1 (Notch signaling) and DUSP6 (STAT3 signaling). Reverse transcriptase-PCR (RT-PCR) confirmed that the expression of CD10, KIAA119, Hey-1 and DUSP6 was significantly increased in MKN28-CSC-LCs compared with those in parental MKN28 cells (Supplementary Figure 3B) .
To investigate the in vivo tumorigenic capability of BMF-induced CSC-LCs, different numbers of MKN28-CSC-LCs were injected into NOD/SCID mice. Mice injected with 10 2 , 10 3 , 10 4 and 10 5 MKN28-CSC-LCs developed tumors 3 months after the injection, whereas none of the mice injected with 1 × 10 5 MKN28 parental cells formed tumor (Figure 2d ). To test whether parental MKN28 cells are tumorigenic, we injected different numbers of MKN28 cells into mice and found that mice injected with 2 × 10 5 and 1 × 10 6 MKN28 cells could form tumors 3 months after the injection (Supplementary Figure 2D ). These data demonstrate that parental MKN28 cells are tumorigenic and that MKN28-CSC-LCs initiate tumorigenesis.
To (Figure 2f ). These xenograft tumors of both first and second transplants showed the same histology and expressed CD44 + in vivo (Figure 2g ). These results show that CD44 + cells are able to re-establish tumor, to self-renew and sustain tumor growth in serially passaged xenografts. Taken together, these results indicate that BMF-induced CD44 + fraction in spheres are gastric CSCs.
BMF-derived IL-6 induces sphere formation of mouse cancer cells The above results suggest that BMF-derived factors contribute to the induction of CSC-LCs. To identify these factors, we conducted Figure 4B) . However, the levels of mIL-β1 and mTNF-α were low and not affected by co-culturing ( Figure 3a ). In addition, we determined the level of human IL-6 (hIL-6) in culture medium and found that the level of hIL-6 did not significantly increased in co-culture medium compared with cancer cell medium (Supplementary Figure 4C) , suggesting that mouse IL-6, but not hIL-6, has a major role in mediating the interactions between BMFs and cancer cells. Using this co-culture system of murine BMFs and human cancer cells, the cell origins of cytokines, chemokines and growth factors were readily distinguished using human or mouse-specific antibodies or primers for PCR. Similarly, the co-culturing of BMFs with mouse MFC cells significantly increased mIL-6 level ( Figure 3c ). These results show that cancer cells activate BMFs to produce mIL-6 in the co-culture system.
We then studied the role of BMF-derived IL-6 in sphere formation of cancer cells. The pre-incubation of BMF-CM or coculture-CM with mIL-6 neutralizing antibody significantly decreased sphere formation of mouse MFC cells (Figure 3d ), but did not affect sphere formation of human MKN28 cells (Supplementary Figure 4D) . These results suggest that mIL-6 did not involve in mBMF-induced sphere formation of human cancer cells. However, JSI-124 (a JAK2 inhibitor) significantly reduced BMF-induced sphere formation in both MKN28 cells and MFC cells (Figure 3e ), suggesting the involvement of JAK2/STAT3 pathway in the sphere formation of human cancer cells. Although TIMP-2 was also significantly increased in co-culture-CM (Figure 3a ), anti-TIMP-2 antibody did not block BMF-CM or co-culture-CM-induced sphere formation of MFC cells (data not shown), indicating that TIMP-2 is not involved in induction of CSCs.
BMF-derived HGF induces sphere formation of human cancer cells To determine which BMF-derived factors contribute to the sphere formation of human cancer cells, we first examined expression levels of cytokines, including SCF, IL-11 and IL-10, which are known to activate STAT3. 20 RT-PCR showed that the mHGF mRNA expression was significantly higher in BMFs co-cultured with human MKN28 cells than that in BMFs cultured alone (Supplementary Figure 4A) , whereas the expression levels of SCF, IL-11 and IL-10 were not different in the co-cultured BMFs compared with the BMFs cultured alone (data not shown). ELISA assay showed that the mHGF level was significantly higher in the co-culture-CM of MKN28 cells and BMFs than that in BMF-CM of BMFs alone (Figure 4a ). Elevated mHGF was also observed in coculture-CM of BMFs and mouse MFC cells (Supplementary Figure 5A) , suggesting that mHGF was generally involved. To determine the effect of HGF/Met signaling on sphere formation, we used crizotinib, a Met kinase inhibitor, 21 to block HGF/Met signaling. Crizotinib treatment significantly reduced BMF-induced sphere formation in MKN28 and MKN45 cells (Figure 4b ), suggesting that murine BMF-derived HGF is a key factor inducing sphere formation of human cancer cells. We noted that the elevated expression of mHGF was parallel with the increased expression of mIL-6 in BMFs (Supplementary Figure 4A ) and hypothesized that IL-6 induced HGF expression in BMFs. We found that both recombinant mIL-6 (rmIL-6) and rhIL-6 treatment significantly increased the mRNA expression of mHGF ( Figure 4c ) and protein levels of p-JAK2 and p-STAT3 in BMFs (Figure 4d ). BMF-CM and rmIL-6 treatment stimulated BMFs to secrete mHGF, whereas these actions were inhibited by JSI-124 (Figure 4e ). These results suggest that BMF-derived IL-6 stimulates BMFs to produce mHGF through the JAK2/STAT3 pathway.
We then investigated the roles of IL-6 and HGF in sphere formation. We found that rhIL-6 or rhHGF treatment induced sphere formation of MKN28 cells and that the combination of rhIL-6 and rhHGF exhibited stronger induction of sphere formation than rhIL-6 or rhHGF alone did (Figure 4f ). Similar results were obtained in MFC cells when treated with rIL-6 and rHGF (Supplementary Figure 5B) . Moreover, rmIL-6 and rmHGF treatment upregulated CD44 expression in MFC cells (Figure 4g Figures 1C and 1D) . Furthermore, the combination of JSI-124 and crizotinib significantly inhibited BMF-induced sphere formation of MFC cells than JSI-124 or crizotinib alone (Supplementary Figure 5C) . These results indicate that BMF-derived HGF directly induces sphere formation of human cancer cells, and that BMF-derived IL-6 indirectly contributes to sphere formation of human cancer cells via the upregulation of mHGF in BMFs. The activation of STAT3 contributes to BMF-induced sphere formation and tumorigenesis To investigate the mechanisms by which BMF-derived IL-6 and HGF induce sphere formation, we treated cancer cells with BMF-CM and found that BMF-CM treatment increased the levels of p-STAT3 and p-Met in MKN28 gastric cancer cells (Figure 5a ). As mIL-6 is inactive to human cancer cells, we proposed that mHGF in BMF-CM may contribute to the STAT3 activation in human cancer cells. Consistent with this hypothesis, rmHGF treatment increased the levels of p-Met and p-STAT3 in human cancer MKN28 cells (Figure 5b) , whereas crizotinib inhibited BMF-CM-induced expression levels of p-Met and p-STAT3 in human gastric cancer cells (Figure 5c ). These results suggest that BMF-derived HGF activates STAT3 and Met signaling in human gastric cancer cells.
To determine the role of STAT3 in BMF-induced sphere formation, we established stable STAT3 knockdown MKN28 colonies (Supplementary Figure 6A) . STAT3 knockdown in MKN28 cells significantly reduced rhIL-6-induced levels of p-STAT3 and TGF-β1 (Figure 5d ) and inhibited BMF-CM-induced sphere formation (Figure 5e ). Furthermore, STAT3 knockdown in MKN28 cells inhibited BMF-promoted tumorigenesis and tumor growth in xenograft models (Figure 5f and Supplementary Figure 6B) . The results show that BMF-derived IL-6/HGF activate STAT3, which induces sphere formation and tumorigenesis.
Cancer cell-derived TGF-β1 activates BMFs The above results that BMF-induced spheres expressed high level of TGF-β1 (Figure 2c ) and that co-cultured cancer cells stimulated BMFs to produce mIL-6 (Figures 3a-c) suggest tumor-derived TGF-β1 as a key factor that activates BMFs. Indeed, ELISA showed that hTGF-β1 level was significantly higher in co-culture-CM than the level in MKN28-CM, MKN45-CM and MFC-CM (Figures 6a-c) , whereas the levels of hIL-1β, hIL-6 and hTNF-α remained low (data not shown). Furthermore, the pre-incubation of anti-human TGF-β1 neutralizing antibody reduced MKN28-CM and co-culture-CMinduced mIL-6 production in BMFs (Figure 6d ). SB-505124 (a TGF-β type I receptor inhibitor) treatment also decreased MKN28 cellinduced mIL-6 production in BMFs (Figure 6e) . Treatment of gastric cancer cells with SB-505124 significantly reduced BMFinduced sphere formation (Figure 6f ). These results show that cancer cell-derived TGF-β1 activates BMFs in a co-culture system. Overexpression of hTGF-β1 and hIL-6 in human gastric cancer tissues To extend our findings to human samples, we investigated the correlation among TGF-β1, IL-6 and HGF in 41 human gastric cancer tissues (Supplementary Table 1 ). Immunohistochemistry (IHC) staining showed that overexpression of hTGF-β1 was observed mainly in cancer cells, whereas the expression of hIL-6 and hHGF was observed in both stromal cells and cancer cells (Figure 7a ). Fifteen out of 41 samples showed high expression of hTGF-β1 and 12 samples showed high expression of hIL-6. Also, 10 samples showed high expression of both hTGF-β1 and hIL-6, and 12 samples showed high expression of both hTGF-β1 and hHGF (Supplementary Table 2 ). Significant correlations between IL-6 and TGF-β1 expression levels, as well as between HGF and TGF-β1 expression levels were found (Supplementary Table 2 ; Po 0.05). The normal gastric tissues showed only weak hTGF-β1 expression, and all normal samples showed no hIL-6 and hHGF expression (Figure 7a ). In addition, we analyzed data from 230 patients with gastric cancer deposited in the Cancer Genome Atlas (TCGA-BR-A4PE) database (Cancer Genome Atlas Network). The expression of HGF was positively correlated with IL-6 expression (Figure 7b ). The expression of TGF-β1 was positively correlated with the expression of IL-6 and HGF (Figures 7c and d) . These results support our proposal that the IL-6/HGF and TGF-β signaling loop is also active in primary human gastric cancers and contributes to the interactions between BMFs and cancer cells, which promote tumor growth.
DISCUSSION
In this study, we demonstrated that BMFs could induce non-CSCs to form CSC-LCs. BMF-derived IL-6 and HGF activated STAT3 in cancer cells, resulting in the upregulation of TGF-β1 in cancer cells. In return, cancer cell-derived TGF-β1 activated BMFs to produce higher levels of IL-6 and HGF. Serum IL-6 level has been shown to be associated with gastric cancer progression. Our observation that the IL-6 level was significantly increased in the BMFs co-cultured with cancer cells suggests that IL-6 is a major BMF-derived factor induced by cancer cells. The role of IL-6 in activating the JAK2/STAT3 pathway in mouse MFC cells is demonstrated by pre-treatment with antimouse IL-6 neutralizing antibody, which significantly inhibited the effect of BMF-CM on activation of JAK2/STAT3 signaling. STAT3 knockdown also significantly reduced BMF-CM-induced activation of JAK2/STAT3 in mouse MFC cells. These results show that STAT3 activation is a key event for BMF-induced CSC-LCs. We also noted that anti-mouse IL-6 neutralizing antibody did not affect the BMF-CM-induced sphere formation of human cancer cells, because of the fact that mIL-6 can not activate hIL-6 receptor. 24 Nevertheless, the BMFs induced the sphere formation of human cancer cells, and the addition of JAK2 inhibitor or the STAT3 knockdown significantly inhibited BMF-CM or BMF-induced sphere formation of human cancer cells. The results suggest that other factors derived from BMFs activate STAT3 in human cancer cells. Other than IL-6, STAT3 can be activated by other cytokines and growth factors including HGF, SCF, IL-11 and IL-10. 8 Our findings that BMF-derived HGF induces sphere formation of human cancer cells is supported by the observation: (1) mHGF was significantly increased in co-culture-CM; (2) rmHGF activated STAT3 signaling in human gastric cancer cells; (3) Met inhibitor significantly suppressed BMFs and BMF-CM-induced sphere formation and STAT3 activation in human cancer cells. In this study, an important finding is that BMF-derived IL-6 activates BMFs to produce mHGF. We found that both rmIL-6 and rhIL-6 activated JAK2/STAT3 signaling and stimulated mHGF expression in BMFs and that the blockade of JAK2/STAT3 signaling reduced HGF production. HGF has been shown to activate JAK2/ STAT3 signaling in liver cells. 25 Myofibroblast-derived HGF has been shown to reprogram colon CSC-LCs through the activation of Wnt signaling. 10 Our results indicate that BMF-derived HGF can activate STAT3 in gastric cancer cells, and BMF-derived IL-6 indirectly contributes to the induction of CSC-LCs through upregulation of HGF. rIL-6 and rHGF could upregulate expression of CD44 in gastric cancer cells, consistent with a recent report. Our results, for the first time, showed that IL-6 and HGF cooperated to induce sphere formation of cancer cells, highlighting the important roles of IL-6 and HGF in tumorigenesis.
We also demonstrated that gastric cancer cells could, in return, activate BMFs. It has been reported that TNF-α and IL-1β activate myofibroblasts, resulting in the production of IL-6.
26,27 TGF-β signaling has been shown to have important roles in the regulation of stemness, 28 epithelial-to-mesenchymal transition 29 and differentiation of fibroblasts. 30 Our finding that gastric cancer cell-derived TGF-β1 activated BMFs is supported by the results that (1) the level of hTGF-β1, but not the levels of hIL-1β and TNF-α, was significantly increased in co-culture-CM; (2) cancer cell-CM and co-culture-CM significantly induced mIL-6 production in BMFs, and anti-human TGF-β1 neutralizing antibody inhibited their effects; (3) TGF-β1 receptor inhibitor SB-505124 reduced BMFinduced sphere formation of cancer cells; (4) BMF-induced CSC-LCs highly expressed TGF-β1; (5) co-overexpression of hTGF-β1 and hIL-6 was found in human gastric cancer tissues. Our results are similar to the recent reports that colon cancer-derived TGF-β activates myofibroblasts, resulting in enhanced tumor growth, invasion and metastasis 31, 32 In summary, we demonstrate for the first time that BMF-derived IL-6 and HGF activate STAT3 in cancer cells to secrete TGF-β1, and BMF-derived IL-6 also activates BMFs to produce HGF. In return, cancer cell-derived TGF-β1 stimulates BMFs to produce IL-6 and HGF, constituting a positive signaling loop that mediates the interactions between BMFs and cancer cells and contributes to upregulating CD44 expression and regulating cancer stemness (Figure 7e ). Our results provide new insights into the mechanisms by which BMFs promote tumorigenesis and suggest potential molecular targets for the prevention and treatment of cancer by inhibiting the interactions between BMFs and cancer cells.
MATERIALS AND METHODS
Cell culture and reagents
Human gastric cancer MKN45 cells and MKN28 cells (RIKEN, Tsukuba, Japan), AGS cells (ATCC, Manassas, VA, USA), SGC-7901 cells and mouse gastric cancer MFC cells (Cell Bank, Shanghai, China), human colon cancer SW620 cells and human liver cancer cells HepG2 (ATCC), were maintained in RPMI-1640 media containing 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco BRL, Grand Island, NY, USA). BMFs (EGFP + ) that were freshly isolated from gastric dysplastic tissues of IL-1β transgenic mice 4 transplanted with EGFP + BMFs according to our previous method.
3 All cell lines were tested for mycoplasma by a PCR method (Stratagene, Santa Clara, CA, USA), and all cell lines were mycoplasma negative. BMFs within 12 generations were used. JSI-124 and NSC33994 (JAK2 inhibitor), crizotinib (c-Met inhibitor) and SB-505124 (TGF-β1 type I receptor inhibitor) were purchased from Sigma (Shanghai, China) and Tocris (Park Ellisville, MO, USA), R&D Systems (Minneapolis, MN, USA), dissolved in dimethyl sulfoxide and stored at − 20°C. Human (h) and mouse (m) recombinant (r) IL-6 and HGF purchased from PeproTech (Rocky Hill, NJ, USA). The anti-mouse IL-6 neutralizing antibody (cat. MAB406) and anti-human TGF-β1 antibody (cat. MAB7364) neutralizing antibodies were purchased from R&D Systems.
Sphere formation assay SCM was prepared by adding basic fibroblast growth factor (10 ng/ml) and epidermal growth factor (EGF; 20 ng/ml) (PeproTech) to the RPMI-1640 medium (Gibco) containing 0.1% bovine serum album. To prepare BMFconditioned medium (BMF-CM), 1.5 × 10 6 BMFs were cultured in 10 ml of serum-free RPMI medium without EGF and basic fibroblast growth factor for 24 h. BMF-CM was collected and stored at − 20°C. To prepare coculture medium of BMFs and cancer cells (co-culture-CM), 1 × 10 6 BMFs and 1 × 10 6 cancer cells were co-cultured in 10 ml of serum-free RPMI-1640 medium without EGF and basic fibroblast growth factor for 24 h. The coculture-CM was collected and stored at -20°C.
Cancer cells (1 × 10 4 ) were cultured alone or co-cultured with BMFs (2 × 10 4 ) in SCM in a six-well plate for 2 weeks. For an indirect co-culture system, cancer cells and BMFs were separately seeded in lower wells and upper transwells (diameter 0.4 μM; Corning, Shanghai, China) in SCM for 2 weeks. In other experiments, cancer cells (1 × 10 2 ) were seeded in an ultralow attachment 96-well plate and cultured with SCM or BMF-CM for 2 weeks. Each group included triple wells and experiments were repeated three times (n = 9). Spheres were recognized as a three-dimensional spherical structure composed of cell colonies. The number of spheres in the entire well was counted, and the percentage of total sphere numbers to the total seeded cells is referred to as 'sphere ratio'.
Antibody array
BMFs (1 × 10 5 ) and MKN28 cells (1 × 10 5 ) were cultured alone or together in 2 ml of RMPI-1640 complete medium in a six-well plate. Twenty-four hours later, cells were washed twice with phosphate-buffered saline and incubated with fresh serum-free RMPI-1640 for another 24 h. Then, the BMF-CM, MKN28-CM and co-culture-CM were collected for antibody array. The mouse cytokine/chemokine array kits (Ray Biotech Inc.) were used to detect a panel of 24 secreted cytokines and chemokines in BMF-CM and co-culture-CM. The human cytokine/chemokine array kits (Ray Biotech Inc.) were used to detect a panel of 24 secreted cytokines and chemokines in MKN28-CM and co-culture-CM according to the manufacturer's recommended protocol. The spot signal densities of array membrane were scanned using the Odyssey Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE, USA). The raw numerical densitometry data were extracted from background. The data of samples were normalized to the positive control signals. The signal intensity for each antigen-specific antibody spot was proportional to the relative concentration of the antigen in that sample. The experiments were repeated twice (n = 3).
Enzyme-linked immunosorbent assay
BMFs (1 × 10 5 ) and cancer cells (1 × 10 5 ) were cultured alone or together in 2 ml of RPMI-1640 complete medium in a six-well plate for 48 h. The BMF-CM, cancer cell conditioned medium and co-culture-CM were collected for ELISA. Each group included triple wells. The experiments were repeated three times (n = 9). Human and mouse cytokines and growth factors in these CM were quantified using anti-human or mouse quantitative ELISA kits according to the manufacturer's instructions (R&D Systems).
Transcription reverse-polymerase chain reaction Total RNA of cells was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. RNA concentration was determined by measuring the absorbance at 260 nm (A260) in a spectrophotometer. Complementary deoxyribonucleic acid was synthesized using a reverse transcription kit (Promega, Beijing, China). Real-time polymerase chain reaction (real-time PCR) was performed with SYBR green (Thermo Fisher Scientific, Beijing, China) according to the manufacturer's instructions using a Bio-Rad MyiQ Thermal cycler (Hercules, CA, USA). The sequences of human and mouse primers were as the following: human E-cadherin, forward primer 5′-ATCGCTTACACCATCCTCAGCCAA-3′, reverse primer 5′-AGCTGTTGCTGTTGTGCTTAACCC-3′; human snail, forward primer 5′-CAATCGGAAGCCTAACTACAGCGA-3′, reverse primer 5′-AGGACAGAGT CCCAGATGAGCATT-3′; human vimentin, forward primer 5′-AGAACCT GCAGGAGGCAGAAGAAT-3′, reverse primer 5′-TTCCATTTCACGCATCTGG CGTTC-3′; human TGF-β1, forward primer 5′-ACACACTGCAAGTGGACATCA ACG-3′, reverse primer 5′-TTCTTCTCCGTGGAGCTGAAGCAA-3′; mouse IL-6, forward primer 5′-CTGCAAGTGCATCATCGTTGTT-3′, reverse primer 5′-CCGG AGAGGAGACTTCACAGAG-3′; human CD10, forward primer 5′-CAACACTCC AAAGCCAAAGAAG-3′, reverse primer 5′-GCTGTCCAAGAAGCACCATA-3′; human KIAA1199, forward primer 5′-CGGTCTATTCCATCCACATCTC-3′, reverse primer 5′-CCAGACGTTCACTCTCTTTCTT-3′; human Hey-1, forward primer 5′-AGACCATCGAGGTGGAGAA-3′, reverse primer 5′-TGGGAAG CGTAGTTGTTGAG-3′; human DUSP6-1, forward primer, 5′-AGCGACTGG AACGAGAATAC-3′, reverse primer 5′-CAAGTAGAGGAAGGGCAAGAT-3′; glyceraldehyde 3-phosphate dehydrogenase, forward primer 5′-GACATC AAGAAGGTGGTGAAGGAG-3′, reverse primer 5′-AACAGGAAATG AGCTT GACAAA-3′. Data were analyzed using the relative standard curve method. Messenger RNA expression levels of the genes were normalized to glyceraldehyde 3-phosphate dehydrogenase. The experiments were repeated three times (n = 3).
Complementary deoxyribonucleic acid microarray and bioinformatics analysis Total RNA was extracted from MKN28 parental cells and MKN28-CSC-LC spheres. Affymetrix microarray analysis, fragmentation of RNA, labeling, hybridization to Human Genome U133 Plus 2.0 microarrays and scanning were performed by the Microarray facility of Cancer Institute of New Jersey, Rutgers University, according to the manufacturer's protocol (Affymetrix, Santa Clara, CA, USA). Gene expression array data of the NCI-60 cell lines implemented with Affymetix HG-U133A and U133B chip platforms were downloaded from the CellMiner database (http://discover.nci.nih.gov/ cellminer/). 31 Heat maps were created using dChip software (http://www. hsph.harvard.edu/cli/complab/dchip/). 6 Classical multidimensional scaling was performed using the standard function of the R program to provide a visual impression of how the various sample groups are related. The average linkage distance was used to assess the similarity of gene expression profiles between MKN28-CLC-LCs and MKN28 parental cells. The error on such a comparison was estimated by combining the standard errors (the standard deviation of pairwise linkages divided by the square root of the number of linkages) of the average linkage distances involved. Gene annotation was performed by the ArrayFusion web tool (http:// microarray.ym.edu.tw/tools/arrayfusion/) and gene enrichment analysis by the DAVID 2008 Bioinformatics Resources (https://david.ncifcrf.gov/). Array data produced in this work are available from the GEO database (accession no. 16884574).
Flow cytometry
FACS was performed on trypsin-dissociated spheres. Cells suspensions were stained with fluorescence-labeled anti-CD44 (BD Biosciences, Danvers, MA, USA; cat. 553133, 1:100), then subjected to FACS analysis using FACS 500 or MoFlo cell sorter (Beckman Coulter, Brea, CA, USA) at the Cytometry and Imaging Core Facility. Dead cells were excluded with propidium iodide staining. All antibodies for FACS analysis were purchased from e-Biosciences (San Diego, CA, USA). Data were analyzed using the Summit software (Beckman Coulter). The experiments were repeated three times (n = 3).
Western blot
Cancer cells and BMFs were lysed with lysis buffer. Protein samples were subjected to sodium dodecyl sulfate-polyacrylamide gels (Bio-Rad) electrophoresis. The gels were transferred onto nitrocellulose membranes (Bio-Rad). The membranes were probed with specific primary antibodies against JAK2 (cat. 3230S), p-JAK2 (cat. 3771S), STAT3 (cat. 9139S), p-STAT3-Y705 (cat. 76315), Met (cat. 8198), p-Met (cat. 3077), Smad2/3 (cat. 5678), p-Smad2 (cat. 8828), vimentin (cat. 3879) (Cell Signaling Technology, Beverly, MA, USA), snail (cat. 92547), E-cadherin (cat. ab15148), TGF-β1 (cat. ab66043), and IL-6 (cat. ab6672) and β-actin (cat. ab6276) (Abcam, Cambridge, MA, USA), incubated with secondary antibodies conjugated to IR fluorophore, Alexa Fluor 680 (Molecular Probes, Thermo Fisher Scientific) or IRdye 800 (Rockland Immunochemicals, Limerick, PA, USA). Antigen-antibody complexes were visualized by the ECL system (Amersham Biosciences, Piscataway, NJ, USA) and scanned using the Odyssey Infrared Imaging System (Li-Cor Biosciences). The experiments were repeated three times (n = 3).
Immunohistochemistry and tissue array
Tissue array samples of human gastric cancer were from Shanghai Ruijin Hospital, Shanghai Jiaotong University School of Medicine. The tissue array section included 41 gastric cancer tissues and 10 normal gastric tissues. The study was performed according to the guidelines of the Medical Ethics Committee of Shanghai Jiaotong University School of Medicine in China and written informed consent was obtained from all patients at study entry. Tissues were formalin fixed, dehydrated and embedded in paraffin.
Immunohistochemical staining was performed as described previously. 33 In brief, the tissues sections were deparaffinized, rehydrated and boiled in 0.01 M sodium citrate, pH 6.0 for antigen retrieval. The endogenous peroxidase activity was quenched. The sections were incubated with anti-TGF-β1 antibody (Abcam, cat. ab66043), anti-IL-6 antibody (Abcam ab6672) or anti-HGF antibody (Abcam, cat. ab189511) overnight at 4°C. Tumor sections were incubated with biotinylated secondary antibodies, streptavidin-biotin complex (Dako, Glostrup, Denmark). Staining was visualized using diaminobenzidine. Representative photos were taken with a Nikon Eclipse E800 microscope equipped with a Nikon DXM1200 digital camera (Nikon Instruments, Melville, NY, USA). The result of the immunohistochemistry for gene expression was judged based on the extent and intensity of staining as follows: (1) the extent of positive cells was estimated as 0 ⩽ 5%, 1 = 6-25%, 2 = 26-50%, 3 = 51-75%, 4 ⩾ 75%. (2) The intensity of staining was judged as 0 = achromatic, 1 = light yellow, 2 = yellow, 3 = brown. The score of the extent of positive cells was multiplied by the score of the intensity of staining, and the combined staining score as follows: (− ) = 0, (+) = 1-4, (++) = 5-8, (+++) = 9-12. Specimens were considered to have low expression of proteins when the score was 0 or +, and were considered to have high expression for genes when the score was ++ or +++. This semiquantitative analysis was done by two independent assessors without before knowledge of the patient outcome. 
IF staining
Tumor xenograft models
Five-week old female healthy athymic nude or NOD/SCID mice from Harlan Laboratories (Indianapolis, IN, USA) were maintained in a sterilized animal room at our animal facility. Mice were randomly divided into different groups and were then injected with different cells. Cancer cells were injected subcutaneously alone or together with BMFs into both flanks of the mice following the protocol no. 09-050 supervised by the Institutional Animal Care and Use Committee of the Ethics Committee. Each group included five mice with 10 injection sites (n = 10). For the injection of spheroid cells, the spheres were digested to single cells and suspended in phosphate-buffered saline. Spheroid cells were injected subcutaneously into both flanks of NOD/SCID mice. Each group included five mice with 10 site injections (n = 10). For the injections of MKN28-STAT3-shRNA cells, each group included four mice with eight site injections (n = 8). For the injections of different number of MKN28 parental cells, each group included three mice with six site injections (n = 6). Tumor size was measured weekly by two researchers without knowledge of cells injected. Tumor development was monitored for 3 months. When the tumor size reached 2 cm 3 , mice were killed, and tumors were processed for histological and immunohistochemical analyses.
Statistical analysis
Unless indicated otherwise, all experiments were repeated three times. Power calculations were performed for animal studies, and the number of mice reflects the number needed to have sufficient power (80%) to measure the expected difference (⩾20%) in the incidences of tumor formation at Po0.05. Based on our preliminary studies, the numbers of animals are included. Results were expressed as means ± s.d. Differences between two groups was analyzed for using a two-tailed Student's t-test for assuming equal variances, with a P-value o0.05 deemed significant. The χ 2 test was applied for comparison of dichotomous variables. One-way analysis of variance test was used for comparing the results of three or BMFs regulate cancer stem cells and tumorigenesis L Zhu et al more groups. All statistical analyses were performed using SPSS 22.0 software (SPSS Inc., Chicago, IL, USA).
ABBREVIATIONS
BMFs, bone marrow-derived myofibroblasts; BMF-CM, BMFconditioned medium; Co-culture-CM, co-culture medium of BMFs and cancer cells; IL-6, interleukin-6; JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3; HGF, hepatocyte growth factor; MSCs, mesenchymal stem cells; EGF, epidermal growth factor; TGF-β, transformation growth factor-β; CSCs, cancer stem cells; CSC-LCs, CSC-like cells; FACS, flow cytometry; ELISA, enzyme-linked immunosorbent assays.
